Inside Absci

We are a generative AI drug creation company on a mission to create better biologics for patients, faster.

160+ Unlimiters

with "multilingual" expertise in Artificial Intelligence, Deep Learning, Protein Engineering, Disease Biology, and Drug Discovery

25+ Programs

from strategic partnerships and internal pipeline candidates as of 12/31/2024

77,000+ Square Feet

of state-of-the-art wet lab in Vancouver WA, Advanced AI Research Lab in NYC, and a Drug Innovation Center in Zug, Switzerland

2,973,648,373

High quality, high-throughput protein-protein interaction data generated weekly

Leading the way in AI drug creation

Absci is a data-first generative AI drug creation company unlocking novel biology through generative AI. Our Integrated Drug Creation™ Platform powers cutting-edge de novo AI and lead optimization models aimed at designing better biologics against difficult-to-drug targets.

Leveraging our synthetic biology roots, Absci has built a proprietary data advantage that fuels a continuous learning cycle: data to train, AI to create, and wet lab to validate in as little as six-weeks.

These iterative cycles drive rapid AI model innovation enabling Absci to advance our mission of creating better biologics for patients, faster.

Innovation doesn't stop and neither do we

We started in 2011 with a vision to make drug discovery more efficient. And as we scaled up our platform we've also scaled up our ambitions to leverage our unique AI and Syn Bio capabilities to create better biologics for patients, against challenging diseases.

Over the past decade we've been generating high quality data at scale for AI training and wet-lab validation, leading to breakthroughs in our Integrated Drug Creation™ Platform which combines the data to train, the AI to create, and the wet lab capable of validating millions of AI-generated designs a week. This allows us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Through our AI and lab-in-the-loop we enable a virtuous cycle that we believe will accelerate us toward fully in silico biologic drug discovery.

Unlocking differentiated biology with generative AI

We are unlocking the potential of next-generation biologics by harnessing deep learning AI to explore a vast therapeutic sequence space inaccessible to conventional discovery methods and creating drugs against previously difficult-to-drug targets.

We are Unlimiters

From the beginning, we set our sights on the seemingly impossible, and we won't settle until we get there. With a state-of-the-art wet lab, artificial intelligence, and above all else a team of brilliant Unlimiters from a variety of disciplines, from pharma to biotech and AI, we're working diligently in pursuit of our mission to create better biologics for patients, faster. We are gritty, creative, and we are pushing the limits of science in a way that no one has done.

Meet our Leadership